LANCL2

NIMML Institute Presents Pioneering Research on Immunometabolic Mechanisms Related to the Pharmacological Activation of LANCL Receptors at Immunology2024, the Annual Meeting of the American Association of Immunologists

Retrieved on: 
星期三, 四月 10, 2024
Health Technology, Other Health, Technology, Pharmaceutical, Oncology, Mental Health, Philanthropy, Infectious Diseases, Genetics, Artificial Intelligence, Clinical Trials, Foundation, Biotechnology, Science, Research, Health, Eosinophilia, Bronchial hyperresponsiveness, NIMML, Swelling, Choline, PBMC, Gastrointestinal tract, Macrophage, Fibrosis, Red, Atopic dermatitis, Brain, TNF, Inflammation, Phenotype, Abstract, Glycolysis, Lupus, T helper 17 cell, IBD, AAI, Psoriasis, OVA, MASH, Plasma, Fed, Ulcerative colitis, Mouse, COL1A1, Microglia, McCormick Place, Therapy, Carbon tetrachloride, HDM, Immunoglobulin E, IL-6, Medicine, Asthma, House, Neutrophil, Patient, Phagocytosis, Ovalbumin, Rheumatoid arthritis, LANCL2, CDAA, UC

The AAI meeting will take place at McCormick Place in Chicago, Illinois from May 3 to May 7, 2024.

Key Points: 
  • The AAI meeting will take place at McCormick Place in Chicago, Illinois from May 3 to May 7, 2024.
  • “We are pleased to present our most recent findings related to the immunometabolic mechanisms of activation of LANCL receptors in inflammation & immunology at this year’s AAI Annual Meeting,” said Dr. Josep Bassaganya-Riera, President and Founding Director of NIMML.
  • NImmune’s portfolio includes first and best-in-class omilancor and NIM-1324, two oral, once-daily agonistic therapeutics that bind and activate the LANCL2 pathway.
  • Title: Pharmacological activation of LANCL2 provides immunometabolic support for the restoration of cognitive function markers in a mouse model of Alzheimer’s disease.

NIMML Institute’s TITAN-X A.I.-Powered Precision Medicine Platform Validated through AbbVie’s Acquisition of Landos Biopharma and Lead Clinical Candidate NX-13

Retrieved on: 
星期一, 三月 25, 2024
Health, Health Technology, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, AbbVie, Ulcerative colitis, Growth, I&I, Cell, ACG, Patient, ABBV, UC, Journal, Biomarker, NIMML, Acquisition, LANCL2, IPO, SLE, Personalized medicine, Volunteering, A.I, IBD, Medicine, Rheumatoid arthritis, Epithelium, DRS, Invention, Therapy, NLRX1, Work, Pharmaceutical industry

and computational modeling capabilities were instrumental for the characterization of NLRX1 as a therapeutic target for autoimmune diseases and the development of NX-13.

Key Points: 
  • and computational modeling capabilities were instrumental for the characterization of NLRX1 as a therapeutic target for autoimmune diseases and the development of NX-13.
  • “Importantly, AbbVie is one of the world’s largest biopharma companies with an incredibly successful I&I franchise that it has built over the last two decades.
  • In addition to Landos Biopharma, Dr. Bassaganya-Riera founded NImmune Biopharma (“NImmune”) with the purpose to advance the clinical development of the LANCL2 portfolio of immunoregulatory precision medicines.
  • Both omilancor and NIM-1324 are guided by precision biomarkers discovered and developed by NIMML’s TITAN-X A.I.-powered Precision Medicine platform.

NImmune Biopharma Presents Positive First-in-Human Data of NIM-1324, a Phase 2 Candidate for Systemic Lupus Erythematosus at the American College of Rheumatology Convergence 2023 (#ACR23)

Retrieved on: 
星期二, 十一月 14, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, San Diego Convention Center, Safety, Randomness, Treatment, LANCL2, Plasma, Hematology, A.I, Rheumatoid arthritis, Urinalysis, American College, SLE, Therapy, IBD, Volunteering, Abstract, Biochemistry, Arthritis, Gastrointestinal tract, Rheumatology, Lupus, ACR, Poster, Pharmaceutical industry, Copper, Ulcerative colitis

“Systemic lupus erythematosus (SLE) has a very high unmet medical need.

Key Points: 
  • “Systemic lupus erythematosus (SLE) has a very high unmet medical need.
  • First in human results of our wholly-owned NIM-1324 in SLE met all primary and secondary endpoints of safety and tolerability.
  • The poster will be available under the “Publications” section of NIMML’s website at www.nimml.org and at the ACR Convergence 2023 virtual poster gallery.
  • Additionally, the peer-reviewed accepted abstracts will be published in a special online supplement of the Arthritis & Rheumatology Journal.

NImmune Biopharma Announces Positive Results of Omilancor in Ulcerative Colitis and Crohn’s disease at the American College of Gastroenterology 2023 Annual Scientific Meeting

Retrieved on: 
星期一, 十月 23, 2023
Research, Clinical Trials, Biotechnology, Health, University, Pharmaceutical, General Health, Science, Education, Patient, American College, UC, The American Journal of Gastroenterology, LANCL2, ACG, Lipid metabolism, Safety, American College of Gastroenterology, Ulcerative colitis, Abstract, New Drug Application, Biomarker, NDA, Neutrophil, American Journal, Gene expression, CD, Pharmaceutical industry, Medical device, Medical imaging

Durable remission was induced in 38.5% of patients in the omilancor group versus 21.4% of patients given placebo (Δ=17.1, P = 0.05).

Key Points: 
  • Durable remission was induced in 38.5% of patients in the omilancor group versus 21.4% of patients given placebo (Δ=17.1, P = 0.05).
  • Title: Efficacy and Safety of Omilancor in a Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of Patients with Crohn’s Disease.
  • Title: Transcriptional Analysis of Colonic Biopsies from Patients with Ulcerative Colitis Treated with Omilancor.
  • Additionally, the peer-reviewed accepted abstracts will be published verbatim in a special supplement to the October 2023 issue of The American Journal of Gastroenterology.

NImmune Biopharma Provides Update on Omilancor Clinical Development Programs in Ulcerative Colitis and Crohn’s Disease

Retrieved on: 
星期三, 五月 17, 2023
Biotechnology, FDA, Other Health, Health, General Health, Pharmaceutical, Biometrics, Other Science, Research, Science, Clinical Trials, Mayo, Myelocyte, Maintenance, FCP, Drug development, TNF, AE, IBD, NDA, A.I, Lupus, Ulcerative colitis, Psoriasis, Open-label trial, LANCL2, US, Acquisition, UC, Patient, Kelly Gebo, New Drug Application, Pharmaceutical industry, Phosphorus

Omilancor is a wholly-owned, once-daily gut-restricted oral first-in-class LANCL2 therapeutic entering Phase 3 clinical testing in UC patients.

Key Points: 
  • Omilancor is a wholly-owned, once-daily gut-restricted oral first-in-class LANCL2 therapeutic entering Phase 3 clinical testing in UC patients.
  • Dr. Josep Bassaganya-Riera, Founder & CEO of NImmune, said, "Following our successful acquisition of the LANCL therapeutic portfolio, we have made meaningful progress in advancing our clinical development programs for omilancor in IBD and NIM-1324 in lupus.
  • Importantly, the omilancor program has taken just over four years since inception to reach Phase 3 initiation, representing significant cost savings compared to traditional drug development timelines.
  • PACIFY II aims to randomize 652 active disease UC patients, with 326 patients receiving 440mg of omilancor and 326 patients receiving placebo.

Josep Bassaganya-Riera Launches NImmune Biopharma with Phase 3-Ready Clinical Candidate Omilancor for the Treatment of Ulcerative Colitis and Crohn’s Disease

Retrieved on: 
星期三, 三月 22, 2023
Health, FDA, Biometrics, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, CD, Volunteering, FCP, RA, File, Lupus, IBD, NDA, Psoriasis, Pharmacokinetics, Toxicity, SLE, RB, LANCL2, Acquisition, UC, Ulcerative colitis, Patient, Standard of care, Rheumatoid arthritis, Autoimmune disease, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Safety, Pharmaceutical industry, Regulatory T cell

NIM-1324 is a Phase-2-ready biomarker-guided once-daily, oral therapeutic for the treatment of Systemic Lupus Erythematosus (SLE) and Rheumatoid Arthritis (RA).

Key Points: 
  • NIM-1324 is a Phase-2-ready biomarker-guided once-daily, oral therapeutic for the treatment of Systemic Lupus Erythematosus (SLE) and Rheumatoid Arthritis (RA).
  • “Our leadership team was instrumental in the creation of the LANCL immunoregulatory portfolio, and brings substantial experience working with omilancor specifically to NImmune.
  • Based on these findings and positive correspondence with the U.S. Food and Drug Administration (FDA), NImmune plans to initiate a Phase 3 randomized, placebo-controlled clinical trial in 2023.
  • An analysis of the Phase 2 data using the 440mg dose and the refined active disease population attained statistically significant clinical remission at week 12.

Landos Biopharma Provides Comprehensive Update on Clinical Development Plans

Retrieved on: 
星期四, 一月 5, 2023
Johns Hopkins School of Medicine, Clinical trial, Diabetic nephropathy, Diabetes, Ulcerative colitis, Steroid, Partnering, Multiple sclerosis, LANCL2, Telephone number (mathematics), MS, Research, Non-alcoholic fatty liver disease, Lupus, Eosinophilic esophagitis, NASH, Psoriasis, Atopic dermatitis, Neurology, Moa, NLRX1, Alzheimer's disease, Disease, Gastroenterology, Rheumatoid arthritis, CNS, Absorption, Patient, Chronic obstructive pulmonary disease, Degenerative disease, RA, Safety, Foundation for the National Institutes of Health, Webcast, SLE, Conference, UC, Race, Endoscopy, International, Pharmaceutical industry, Vaccine, MD, Asthma

Broader, Novel Pipeline Poised for Partnering and Continued Development in the Future;

Key Points: 
  • Broader, Novel Pipeline Poised for Partnering and Continued Development in the Future;
    NEW YORK, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP) (“Landos” or the “Company”), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced a comprehensive update on its future clinical development plans.
  • “After thorough analysis and careful consideration, we are confident that focusing our resources toward NX-13’s clinical development has the potential to deliver the most value for Landos and our shareholders,” said Gregory Oakes, President and Chief Executive Officer of Landos.
  • “Our goal is to evolve Landos from a discovery-based organization into an immunology development powerhouse.
  • The Company will host a live webcast to provide a comprehensive update on Landos’ clinical development plans at 8:00 AM ET today.

Landos Biopharma Reports Third Quarter 2022 Results and Provides Business Update

Retrieved on: 
星期四, 十一月 10, 2022
GLOBE, Security (finance), Review, Rheumatoid arthritis, Ulcerative colitis, UC, SLE, SEC, NASDAQ, Degenerative disease, Safety, U.S. Securities and Exchange Commission, Endoscopy, LANCL2, Company, Report, Clinical trial, Research, Patient, CEO, Therapy, Crohn's disease, RA, NLRX1, COVID-19, PLXDC2, Pharmaceutical industry, Dentistry

NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced financial results for the third quarter ended September 30, 2022, and provided a business update.

Key Points: 
  • NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced financial results for the third quarter ended September 30, 2022, and provided a business update.
  • Landos has made significant progress advancing our clinical-stage programs omilancor, NX-13 and LABP-104, said Gregory Oakes, President and CEO of Landos.
  • Research and development expenses were $4.9 million for the third quarter of 2022, compared to $9.3 million in the third quarter of 2021.
  • General and administrative expenses were $3.0 million for the third quarter of 2022, compared to $3.1 million in the third quarter of 2021.

Landos Biopharma Announces Appointment of Fabio Cataldi, MD, as Chief Medical Officer

Retrieved on: 
星期二, 九月 6, 2022
SUN, AbbVie, Novartis, COVID-19, Security (finance), Inflammatory bowel disease, Rheumatoid arthritis, Bureau of Medicine and Surgery, Research, Degenerative disease, Biogen, NASDAQ, Sale, Food, GI, IBD, SEC, PLXDC2, Beth Israel Deaconess Medical Center, U.S. Securities and Exchange Commission, Internal, Immunology, Chief medical informatics officer, GLOBE, Constipation, Company, Lupus, Therapy, Report, Drug, Drug discovery, LANCL2, Gastroenterology, Dermatology, Drug development, Ulcerative colitis, NLRX1, Patient, Arena Pharmaceuticals, Pharmaceutical industry, Medicine, UC, Pfizer, MD

NEW YORK, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced the appointment of Fabio Cataldi, MD, as the Companys Chief Medical Officer, effective September 5, 2022.

Key Points: 
  • NEW YORK, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced the appointment of Fabio Cataldi, MD, as the Companys Chief Medical Officer, effective September 5, 2022.
  • Dr. Cataldi joins Landos with more than twenty years of successful experience in the development and commercialization of innovative therapies.
  • Fabios appointment as Chief Medical Officer is an important step as we look to continue selectively growing our leadership team with the talent and expertise that we need to successfully advance our pipeline.
  • Landos Biopharma is a clinical-stage biopharmaceutical company focused on the discovery and development of oral therapeutics for patients with autoimmune diseases.

Landos Biopharma Reports Second Quarter 2022 Results and Provides Business Update

Retrieved on: 
星期四, 八月 11, 2022
U.S. Securities and Exchange Commission, Safety, LANCL2, NLRX1, SLE, CEO, GLOBE, Endoscopy, NEW, SEC, Clinical trial, Security (finance), RA, UC, Patient, COVID-19, Company, PLXDC2, Therapy, Ulcerative colitis, NASDAQ, Research, Tolerability, Report, Degenerative disease, Rheumatoid arthritis, Pharmaceutical industry, Dentistry

NEW YORK, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced financial results for the second quarter ended June 30, 2022, and provided a business update.

Key Points: 
  • The results support our belief that NX-13 has the potential to be an important new oral, once-daily treatment for UC.
  • Research and development expenses were $6.6 million for the second quarter of 2022, compared to $11.5 million in the second quarter of 2021.
  • General and administrative expenses were $4.7 million for the second quarter of 2022, compared to $2.6 million in the second quarter of 2021.
  • Landos Biopharma, Inc. Unaudited Condensed Consolidated Statements of Operations (in thousands, except share and per share amounts)